Periostat litigation settled
Executive Summary
CollaGenex, West-ward settle litigation over periodontal therapy Periostat. West-ward stipulates CollaGenex' patents are valid and infringed by its ANDA; CollaGenex will pay $700,000 to cover portion of West-ward legal fees. Litigation with Mutual continues. CollaGenex won a preliminary injunction against approval of generics in July (1"The Pink Sheet" July 28, 2003, p. 10)...
You may also be interested in...
CollaGenex Periostat Lawsuit Hinges On FDA “Antibiotic” Determination
A federal judge must determine whether CollaGenex' Periostat is properly classified as an "antibiotic" after preliminarily enjoining FDA from approving generic versions of doxycycline hyclate 20 mg
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.